Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Director Sells $69,410.70 in Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating) Director Anne Oriordan sold 466 shares of the company’s stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $148.95, for a total value of $69,410.70. Following the completion of the sale, the director now directly owns 9,245 shares in the company, valued at approximately $1,377,042.75. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

JAZZ stock opened at $146.49 on Friday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 2.06 and a current ratio of 3.39. The business has a fifty day simple moving average of $158.32 and a 200-day simple moving average of $142.76. Jazz Pharmaceuticals plc has a 52 week low of $117.64 and a 52 week high of $189.00.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Rating) last released its quarterly earnings data on Wednesday, May 4th. The specialty pharmaceutical company reported $3.73 EPS for the quarter, topping analysts’ consensus estimates of $3.00 by $0.73. The business had revenue of $813.72 million during the quarter, compared to the consensus estimate of $853.73 million. Jazz Pharmaceuticals had a positive return on equity of 22.45% and a negative net margin of 13.63%. The business’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same period in the prior year, the firm posted $3.42 EPS. Research analysts expect that Jazz Pharmaceuticals plc will post 14.73 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Private Capital Group LLC increased its holdings in Jazz Pharmaceuticals by 1,975.0% in the 1st quarter. Private Capital Group LLC now owns 166 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 158 shares in the last quarter. Lloyd Advisory Services LLC. acquired a new stake in Jazz Pharmaceuticals in the 1st quarter valued at $29,000. Quent Capital LLC acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at $31,000. National Bank of Canada FI acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at $35,000. Finally, C M Bidwell & Associates Ltd. acquired a new stake in Jazz Pharmaceuticals in the 1st quarter valued at $45,000. Hedge funds and other institutional investors own 93.23% of the company’s stock.

A number of equities research analysts recently issued reports on JAZZ shares. Cowen upped their target price on Jazz Pharmaceuticals from $200.00 to $225.00 in a research note on Thursday, May 5th. Truist Financial increased their price target on Jazz Pharmaceuticals from $180.00 to $200.00 in a research note on Thursday, January 20th. Piper Sandler reduced their price target on Jazz Pharmaceuticals from $197.00 to $193.00 in a research note on Thursday, May 5th. The Goldman Sachs Group lowered Jazz Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $202.00 to $196.00 in a research note on Wednesday, April 6th. Finally, Royal Bank of Canada reduced their price target on Jazz Pharmaceuticals from $216.00 to $214.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 2nd. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $206.47.

Jazz Pharmaceuticals Company Profile (Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Further Reading

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.